Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2009
10/28/2009CN100554410C Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regeneration
10/28/2009CN100553684C Method for preparing MRI visible, liver target and degradable nano-gene vector
10/28/2009CN100553683C Peptide-DNA double vaccine based on T-cell epitope for anti-Schistosoma japonicum infection
10/28/2009CN100553682C G type non-viral vector and pharmaceutical composition containing same
10/28/2009CN100553612C Preparing process of nano c-FLIP antisense oligonucleotide particle
10/27/2009US7608707 siRNA targeting survivin
10/27/2009US7608698 Muscular disorders; cardiovascular disorders; cell transformed with nucleic acid; culture product
10/27/2009US7608683 Human leukocyte antigen pan DR-binding peptides for use in the treatment of infections, inflammatory, autoimmune and cancer diseases; has heat shock protein that is capable of binding to MHC class II molecules
10/27/2009US7608451 Expression vector comprising kinase nucleotide sequence for use as tool in transformation and expression of heterologus genes in mamalian cells
10/27/2009US7608449 Methods and compositions related to high-titer pseudotyped retroviruses
10/27/2009US7608422 Gene therapy; vaccines; inducing antibodies and/or cytotoxic or helper T lymphocytes
10/27/2009US7608409 Screening assay using G-protein coupled receptor protein OT7T175
10/27/2009US7608401 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
10/27/2009US7608276 vaccines, immunogenic compositions; diagnostics, enzymatic studies and targets for antibiotics; for treating Staphylococcus aureus infection
10/27/2009US7608256 Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
10/27/2009US7608255 Replication-competent anti-cancer vectors
10/27/2009CA2372085C L-ribo-lna analogues
10/27/2009CA2163364C Self-assembling polynucleotide delivery system comprising dendrimer polycations
10/22/2009WO2009129523A2 Compositions and methods for nucleic acid delivery
10/22/2009WO2009129281A2 Compositions and methods for delivering inhibitory oligonucleotides
10/22/2009WO2009128936A2 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
10/22/2009WO2009127797A1 Agent and method for the reduction of parasitic flatworms
10/22/2009WO2009127754A1 USE OF eNOS INHIBITORS IN NERVOUS REGENERATION
10/22/2009WO2009127719A1 Method for obtaining ngn3-expressing cells and insulin producing-beta cells
10/22/2009WO2009127705A1 Novel therapeutical tools and methods for treating blindness
10/22/2009WO2009127537A1 Post release modification of viral envelopes
10/22/2009WO2009127060A1 Novel lipid formulations for nucleic acid delivery
10/22/2009WO2009105355A3 A novel neospora caninum vaccine
10/22/2009WO2009099959A3 Tumor cell expression of neuropilin as a target for cancer therapy
10/22/2009WO2009099820A3 Modulating body weight
10/22/2009WO2009022174A3 Non-aggregating virus formulation
10/22/2009WO2008132729A3 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
10/22/2009US20090265796 DNA segment that confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell; genetic engineering
10/22/2009US20090264634 Sequences characteristic of hypoxia-regulated gene transcription
10/22/2009US20090264515 Polynucleotide therapy
10/22/2009US20090264506 Delivery of polynucleotide agents to the central nervous system
10/22/2009US20090264505 Methods and compositions for rnai mediated inhibition of gene expression in mammals
10/22/2009US20090264504 For modulating human immunodeficiency virus (HIV) gene expression ; nucleic acids with a pyrimidine modification; AIDS
10/22/2009US20090264501 Methods and Compositions to Inhibit P2x7 Receptor Expression
10/22/2009US20090264381 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
10/22/2009US20090264364 Genes implicated in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications
10/22/2009US20090263916 Antagonists of HMG1 for treating inflammatory conditions
10/22/2009US20090263898 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
10/22/2009US20090263860 Nucleotide sequences coding polypeptides for use in the diagnosis and treatment of cell proliferative disorders
10/22/2009US20090263847 Lsr receptor, its activity, its cloning and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications
10/22/2009US20090263788 Efficient algorithm for pcr testing of blood samples
10/22/2009US20090263783 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
10/22/2009US20090263417 Multi-subtype FIV vaccines
10/22/2009US20090263404 Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor
10/22/2009US20090263389 Use of TGF-Beta Antagonists to Treat or to Prevent Chronic Transplant Rejection
10/22/2009US20090263365 Methods and compositions for transforming dendritic cells and activating cells
10/22/2009US20090263364 Method and constructs for delivering double stranded rna to pest organisms
10/22/2009US20090263358 autologously transplanting hematopoietic progenitor cell population which has been treated with antibody (monoclonal, chimeric, or humanized; not conjugated to toxin or cytolytic agent); radiotherapy
10/22/2009CA2721635A1 Compositions comprising halorhodopsin
10/22/2009CA2721333A1 Novel lipid formulations for nucleic acid delivery
10/22/2009CA2720363A1 Compositions and methods for delivering inhibitory oligonucleotides
10/21/2009EP2110385A1 Stabilized factor VIII with engineered disulfide bonds
10/21/2009EP2110384A1 Hepatopoietin and use thereof
10/21/2009EP2110142A2 Inhibition of secretion from non-neuronal cells
10/21/2009EP2109361A1 A transgenic animal and a method of producing it
10/21/2009EP1648521B1 Compositions and methods for treating cardiac dysfunction
10/21/2009EP1590467B1 Use of regulatory sequences for specific, transient expression in neuronal determined cells
10/21/2009EP1501465B1 Vectors having both isoforms of beta-hexosaminidase
10/21/2009EP1423413B1 Peptidic compounds selectively binding to p-selectin
10/21/2009EP1292680B1 Agonist anti-trk-c monoclonal antibodies
10/21/2009EP1207877B1 Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids
10/21/2009EP1117672B1 Antisense modulation of survivin expression
10/21/2009EP1047784B1 Neissera meningitidis antigens
10/21/2009EP0986372B1 Vesicular complexes and methods of making and using the same
10/21/2009CN101563463A Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus
10/21/2009CN101563096A Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
10/21/2009CN101563081A Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
10/21/2009CN101560521A VA1-missing adenovirus vector for expressing small interfering RNA (siRNA) and constructing method and application thereof
10/21/2009CN101560517A Preparation process of interleukin-2 genetic engineering gastric carcinoma cell tumour vaccine
10/21/2009CN101560514A Bridge molecule 1-siRNA interference sequence and fusion expression vector thereof
10/21/2009CN101560502A Herpes virus strains for gene therapy
10/21/2009CN101560500A Cell strain LaDR5 for secreting tumor necrosis factor receptor induced antibody
10/21/2009CN101560498A Preparation method of inactivated interleukin-2 genetic engineering gastric carcinoma cells
10/21/2009CN101560497A Preparation method of inactivated interleukin-2 genetic engineering gastric carcinoma cell tumour vaccine
10/21/2009CN101560245A CTL epitope polypeptide of avian influenza H5N1 virus and application thereof
10/21/2009CN101559241A Hyaluronic acid-hydroxyapatite nano composite sphere and preparation method
10/21/2009CN100552027C Gene families associated with cancers
10/20/2009US7605249 To deliver specifically tailored small interfering RNA as therapeutic agents for treatment of Parkinson's disease
10/20/2009US7605246 Genes differentially expressed in breast cancer
10/20/2009US7605142 used to treat tumor (osteosarcoma or Ewing's sarcoma); restenosis
10/20/2009US7605140 Endothelial growth factors; antiischemic agents; neovascularization
10/20/2009US7604989 Prevention or delaying apoptosis in recombinant cell; obtainceks transforme with nucleotide sequences coding antiapoptotic agents, express sequences, monitor adjustment in apotosis activity
10/20/2009US7604958 Transfection, culturing; electrophoresis
10/20/2009US7604810 Conserved Neisserial antigens
10/20/2009US7604808 Circovirus sequences associated with piglet weight loss disease (PWD)
10/20/2009US7604803 Codelivery to a cell of nucleic acid and assistor protein (antigen) where the nucleic acid encodes an antigenic protein or which shares an epitope(s) with the assistor protein; the nucleic acid is entrapped in liposome intravesicular space; assistor protein is on the liposome surface; synergistic
10/20/2009CA2250085C Modulators of tnf receptor associated factor (traf), their preparation and use
10/20/2009CA2227467C Helper virus-free herpesvirus vector packaging system
10/15/2009WO2009126933A2 Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
10/15/2009WO2009126805A2 Therapeutic tarageting of mmps in neutral liposomes
10/15/2009WO2009126789A2 Engineering and delivery of therapeutic compositions of freshly isolated cells
10/15/2009WO2009126651A2 Mat ii subunit rnai and therapeutic methods using same
10/15/2009WO2009126650A2 Inhibition of angiognesis
10/15/2009WO2009126308A2 Compositions and methods for vaccine and virus production
10/15/2009WO2009126306A2 Compositions and methods for detecting egfr mutations in cancer
1 ... 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 ... 870